AIDS Alert Archives – December 1, 2009
December 1, 2009
View Issues
-
Can the HIV world create effective, sustainable adherence interventions?
HIV antiretroviral adherence interventions have been broadly employed in the roughly dozen years since medication adherence became an issue. Interventions have combined medical and behavioral science, sometimes pairing technological innovation with conventional socio-behavioral counseling and education. -
Technological advances in adherence interventions are not expected panacea
Researchers and clinicians working on medication adherence interventions have a variety of technological tools to help them both measure and, theoretically, improve medication adherence. -
Stigma's toll on well-being, adherence and behaviors
HIV stigma has existed since the world first learned about AIDS, and it's been commonly discussed, but clinicians still need to know more about its impact on their patients' well-being, adherence, and behaviors. -
HIV/AIDS News
Study released on AIDS vaccine results from Thailand; Texas surgeon agrees to treat HIV/AIDS patients -
H1N1 vaccine, treatment updates for HIV/AIDS pts
The Centers for Disease Control and Prevention recently updated guidance on H1N1 pandemic influenza A and adults with HIV Infection. The latest Q&A postings on vaccination and treatment issues are summarized as follows. -
Journal Review
It is essential to sustain a robust HIV/AIDS research agenda to develop interventions which have the potential to be "truly transforming," researchers report. -
FDA Notifications
On Aug. 6, 2009, the FDA granted tentative approval for a generic formulation of lamivudine tablets, 150 mg and 300 mg, manufactured by Strides Arcolab Limited of Bangalore, India, indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults. -
'Half the sky" is dark: Women and HIV/AIDS
Women, as the Chinese proverb observes, are "half the sky." Unfortunately, they are also now half of the HIV/AIDS epidemic.